Anemia Treatments
Find Anemia Treatments
Aranesp
What is Aranesp (Darbepoetin)?
Approved To Treat
Related Clinical Trials
Summary: This study is a prospective randomized controlled trial to assess the efficacy of erector spinae plane (ESP) blocks in patients undergoing autologous free flap breast reconstruction. Currently, patients undergoing this procedure remain in the hospital initially for flap monitoring until discharge criteria is met, when pain is adequately controlled and patient is able to ambulate independently. Pro...
Summary: The goal of this Phase 2 clinical trial is to learn if adding romiplostim to standard erythropoiesis-stimulating agent (ESA) therapy is safe and tolerated in adults with chronic kidney disease who are on hemodialysis and have anemia that has not responded well to ESAs. The study will mainly check platelet counts and side effects. The main questions it aims to answer are: How many participants keep...
Summary: This is a single arm open-label Phase II trial of luspatercept and darbepoetin alfa in non-mutated SF3B1 , lower-risk, RBC transfusion dependent MDS participants with an endogenous erythropoietin (EPO) level \< 500 IU/L.
Related Latest Advances
Brand Information
- In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL [see Warnings and Precautions (5.1)].
- No trial has identified a hemoglobin target level, Aranesp dose, or dosing strategy that does not increase these risks[see Dosage and Administration (2.2)].
- Use the lowest Aranesp dose sufficient to reduce the need for red blood cell (RBC) transfusions [see Warnings and Precautions (5.1)].
- ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers [see Warnings and Precautions (5.2)].
- To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions [see Dosage and Administration (2.3)].
- Use ESAs only for anemia from myelosuppressive chemotherapy [see Indications and Usage (1.2)].
- ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure [see Indications and Usage (1.3)].
- Discontinue following the completion of a chemotherapy course [see Dosage and Administration (2.3)].
- Injection: 25 mcg, 40 mcg, 60 mcg, 100 mcg, and 200 mcg
- Injection: 10 mcg/0.4 mL, 25 mcg/0.42 mL, 40 mcg/0.4 mL, 60 mcg/0.3 mL, 100 mcg/0.5 mL,
- Uncontrolled hypertension
- Pure red cell aplasia (PRCA) that begins after treatment with Aranesp or other erythropoietin protein drugs
- Serious allergic reactions to Aranesp
- Increased Mortality, Myocardial Infarction, Stroke, and Thromboembolism
- Increased Mortality and/or Increased Risk of Tumor Progression or Recurrence in Patients with Cancer
- Hypertension
- Seizures
- Pure Red Cell Aplasia
- Serious Allergic Reactions
- Severe Cutaneous Reactions
- Seizures
- Pure Red Cell Aplasia
- Serious Allergic Reactions
- Severe Cutaneous Reactions
- Of the increased risks of mortality, serious cardiovascular reactions, thromboembolic reactions, stroke, and tumor progression
- To undergo regular blood pressure monitoring, adhere to prescribed anti-hypertensive regimen and follow recommended dietary restrictions.
- To contact their healthcare provider for new-onset neurologic symptoms or change in seizure frequency.
- Of the need to have regular laboratory tests for hemoglobin.
- Importance of following the Instructions for Use.
- Dangers of reusing needles, syringes, or unused portions of single-dose vials.
- Proper disposal of used syringes, needles, and unused vials, and of the full container.
- Importance of informing healthcare provider if difficulty occurs when measuring or administering partial doses from the Aranesp prefilled syringe. If difficulty occurs, use of other syringes or Aranesp vial may be considered.
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, CA 91320-1799 U.S.A.
U.S. License Number 1080
Patent: http://pat.amgen.com/aranesp/

















